BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...model, which has been widely successful. It was through this method that CFF started supporting Aurora Biosciences Corp....
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...Review of the transisomer of cyclosporine A analog that inhibits calcineurin. In the Phase III AURORA...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...Rep. ; published online April 7, 2020 doi:10.1016/j.celrep.2020.03.049 CONTACT: Nathan A. Dahl, University of Colorado, Aurora...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...with €10 million in backing from two Italian biopharmas. AurorA Science will be managed by AurorA-TT...
...pharma region Europe and head of oncology Europe at Swiss pharma Novartis AG (NYSE:NVS; SIX:NOVN). AurorA...
...s.r.l. and specialty pharma Italfarmco S.p.A. Beyond providing the €10 million ($11 million) in capital, AurorA-TT...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...than one indication are shown more than once, such as the Phase I/II programs of Aurora...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...Dec. 5 after reporting that voclosporin met primary and secondary endpoints in the Phase III AURORA...
BioCentury | Dec 5, 2019
Company News

Dec. 4 Company Quick Takes: Allakos on the block?; plus Aurinia, Tecentriq, Gatehouse-AZ, Novartis-Amazon, Merck KGaA-Ping An and ICT

...after-hours trading when it reported voclosporin met primary and secondary endpoints in the Phase III AURORA...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...call late Monday that both are due to read out next year. The Phase IIb AURORA...
BioCentury | Sep 12, 2019
Distillery Therapeutics

A mAb blocking IL-1 co-receptor for inflammatory, autoimmune diseases

...published online Aug. 19, 2019 doi:10.1038/s41590-019-0467-1 CONTACT: Charles A. Dinarello, University of Colorado Denver, Aurora...
BioCentury | Jul 26, 2019
Emerging Company Profile

Limbix: A virtual treatment for the reality of depression

...Institutions Mentioned Harvard University, Cambridge, Mass. Limbix, Palo Alto, Calif. National Mental Health Innovation Center, Aurora...
Items per page:
1 - 10 of 787
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...model, which has been widely successful. It was through this method that CFF started supporting Aurora Biosciences Corp....
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...Review of the transisomer of cyclosporine A analog that inhibits calcineurin. In the Phase III AURORA...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...Rep. ; published online April 7, 2020 doi:10.1016/j.celrep.2020.03.049 CONTACT: Nathan A. Dahl, University of Colorado, Aurora...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...with €10 million in backing from two Italian biopharmas. AurorA Science will be managed by AurorA-TT...
...pharma region Europe and head of oncology Europe at Swiss pharma Novartis AG (NYSE:NVS; SIX:NOVN). AurorA...
...s.r.l. and specialty pharma Italfarmco S.p.A. Beyond providing the €10 million ($11 million) in capital, AurorA-TT...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...than one indication are shown more than once, such as the Phase I/II programs of Aurora...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...Dec. 5 after reporting that voclosporin met primary and secondary endpoints in the Phase III AURORA...
BioCentury | Dec 5, 2019
Company News

Dec. 4 Company Quick Takes: Allakos on the block?; plus Aurinia, Tecentriq, Gatehouse-AZ, Novartis-Amazon, Merck KGaA-Ping An and ICT

...after-hours trading when it reported voclosporin met primary and secondary endpoints in the Phase III AURORA...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...call late Monday that both are due to read out next year. The Phase IIb AURORA...
BioCentury | Sep 12, 2019
Distillery Therapeutics

A mAb blocking IL-1 co-receptor for inflammatory, autoimmune diseases

...published online Aug. 19, 2019 doi:10.1038/s41590-019-0467-1 CONTACT: Charles A. Dinarello, University of Colorado Denver, Aurora...
BioCentury | Jul 26, 2019
Emerging Company Profile

Limbix: A virtual treatment for the reality of depression

...Institutions Mentioned Harvard University, Cambridge, Mass. Limbix, Palo Alto, Calif. National Mental Health Innovation Center, Aurora...
Items per page:
1 - 10 of 787